Metabolic Syndrome in Thyroid Disease.

2区医学 Q2 Medicine

Frontiers of Hormone Research Pub Date : 2018-01-01 Epub Date: 2018-04-05 DOI:10.1159/000485996

K Alexander Iwen, Rebecca Oelkrug, Hannes Kalscheuer, Georg Brabant

引用次数: 17

Abstract

Cardiometabolic risk factors like abdominal obesity, hyperglycemia, low high-density lipoprotein (HDL) cholesterol, elevated triglycerides, and hypertension are defined as metabolic syndrome (MetS), which represents one of the most frequent endocrine disorders particularly in a society with increasing weight problems. As more and more evidence is accumulated that thyroid hormones affect components of the MetS, the present review aims to summarize the rapidly expanding knowledge on the pathophysiological interaction between thyroid hormone status and MetS. The review is based on a PubMed search for combinations of thyroid hormone action and MetS, blood pressure, hypertension, hyperlipidemia, cholesterol, HDL cholesterol, glucose, diabetes mellitus, body weight, or visceral fat. A special focus was given for manuscripts published after 2000 but we included seminal papers published before year 2000 as well.

查看原文本刊更多论文

甲状腺疾病的代谢综合征。

心脏代谢危险因素，如腹部肥胖、高血糖、低高密度脂蛋白(HDL)胆固醇、甘油三酯升高和高血压被定义为代谢综合征(MetS)，这是最常见的内分泌失调之一，特别是在体重问题日益严重的社会中。随着越来越多的证据表明甲状腺激素影响代谢代谢的组成部分，本文旨在总结甲状腺激素状态与代谢代谢之间病理生理相互作用的快速扩展的知识。该综述基于PubMed对甲状腺激素作用与代谢当量、血压、高血压、高脂血症、胆固醇、高密度脂蛋白胆固醇、葡萄糖、糖尿病、体重或内脏脂肪组合的搜索。特别关注2000年以后发表的手稿，但我们也包括2000年以前发表的开创性论文。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.